Telix: Telix submits BLA to US FDA for TLX250CDx kidney cancer imaging
Telix, a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies, announces that it has submitted its
Read full article »
Telix is an Australia-based biopharmaceutical firm that researches and develops molecularly targeted radiation therapeutic products for the treatment of cancer.
Read more